Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.51 |
| ▸ | ITGAV | P06756 | 20/20 | 0.51 |
| ▸ | ITGB5 | P18084 | 16/20 | 0.51 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.46 |
| ▸ | ITGB6 | P18564 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7095454 | 0.90 | ITGB3 (0.51) | ITGB3ITGAVITGB5ITGB1ITGB6 | |
| SCHEMBL7099242 | 0.81 | ITGB3 (0.49) | ITGB3ITGAVITGB5ITGB1ITGB6 | |
| SCHEMBL7403607 | 0.78 | ITGAV (0.54) | ITGB3ITGAVITGB5ITGB1ITGB6 | |
| SCHEMBL7096359 | 0.77 | ITGB3 (0.54) | ITGB3ITGAVITGB5ITGB1 | |
| SCHEMBL7094539 | 0.77 | ITGAV (0.53) | ITGB3ITGAVITGB5ITGB1ITGB6 | |
| SCHEMBL7097098 | 0.76 | ITGB3 (0.53) | ITGB3ITGAVITGB5ITGB1 | |
| SCHEMBL7096049 | 0.76 | ITGB3 (0.56) | ITGB3ITGAVITGB5ITGB1 | |
| SCHEMBL7100120 | 0.76 | ITGB3 (0.58) | ITGB3ITGAVITGB5ITGB1 | |
| SCHEMBL7101413 | 0.72 | ITGB3 (0.54) | ITGB3ITGAVITGB5ITGB1 | |
| SCHEMBL7012378 | 0.72 | ITGAV (0.49) | ITGB3ITGAVITGB5ITGB1ITGB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1194151-A4 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2003-01-15 | — | — | EP | claimed |
| EP-1194151-A1 | INTEGRIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2002-04-10 | — | — | EP | claimed |
| WO-2000078317-A1 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2000-12-28 | — | — | WO | claimed |
| EP-1194151-A4 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2003-01-15 | — | — | EP | disclosed |
| EP-1194151-A1 | INTEGRIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2002-04-10 | — | — | EP | disclosed |
| US-6358970-B1 | FOR THERAPY AND PROPHYLAXIS OF OSTEOPOROSIS, AND INHIBITING VASCULAR RESTENOSIS, DIABETIC RETINOPATHY, MACULAR DEGENERATION, ANGIOGENESIS, ATHEROSCLEROSIS, INFLAMMATION, ARTHRITIS, VIRAL DISEASE, CANCER, AND METASTATIC TUMOR GROWTH | MERCK & CO., INC. | 2002-03-19 | — | — | US | disclosed |
| WO-2000078317-A1 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2000-12-28 | — | — | WO | disclosed |